JAK Inhibitor Safety in Atopic Dermatitis: Long-Term Epidemiology Data
Dermatology experts presented long-term safety data for JAK inhibitors like upadacitinib and abrocitinib in treating atopic dermatitis. The findings suggest that seven-year safety profiles for these drugs are comparable to other established treatments, with ongoing research into cardiovascular risk factors.
Why it matters
This data provides critical reassurance for clinicians and patients regarding the long-term safety of advanced dermatological therapies.
Christopher Bunick, MD, PhD, associate professor of dermatology at the Yale School of Medicine and editor in chief of Dermatology Times, presented in a JAK inhibitor symposium at Fall Clinical 2026 focused on the safety narrative for JAK inhibitors in atopic dermatitis. Bunick and his fellow presenters covered the limitations of the ORAL Surveillance study and the latest epidemiology data.
Epidemiology Data for Upadacitinib and Abrocitinib
The presenters reviewed rates of MACE, VTE, and malignancy with upadacitinib (Rinvoq; AbbVie) and abrocitinib (Cibinqo; Pfizer) in atopic dermatitis. They compared those adverse event rates with other medicines, including the IL-13 biologic tralokinumab (Adbry; LEO Pharma). For the first time, they also presented a comparison with oral apremilast (Otezla; Amgen), an agent dermatologists consider very safe.
Bunick said the long-term atopic dermatitis data now span around 7 years for upadacitinib and abrocitinib.
Get smarter about the news
Sign up free for a feed built around what you actually care about, Dive Deeper research on any story, and the full text of every article.
Create free accountAlready have an account? Sign in